Markets:

Overview

News

Currencies

International

Treasuries

Denali Therapeutics Inc. - Common Stock (NQ:DNLI)

19.87 -0.13 (-0.65%)

Delayed Quote Updated: 1:57 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Denali Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >

Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

AVLAYAH revenue hit $3.6M in first full quarter post-approval.

Via The Motley Fool

Topics Earnings

Denali Therapeutics (NASDAQ:DNLI) Shows Perfect Technical Setup for a Breakout ↗

August 12, 2026

Via Chartmill

Denali Therapeutics Q2 Earnings Call Highlights ↗

August 06, 2026

Denali Therapeutics (NASDAQ:DNLI) reported $3.6 million in net product revenue from AVLAYAH during the second quarter of 2026, its first full quarter of commercial availability, as the company expanded...

Via MarketBeat

Topics Earnings

Denali Therapeutics (NASDAQ:DNLI) Drops as Q2 AVLAYAH Revenue Misses Estimates ↗

August 06, 2026

Via Chartmill

4 Analysts Assess Denali Therapeutics: What You Need To Know ↗

February 28, 2024

Via Benzinga

Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗

May 18, 2026

This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.

Via The Motley Fool

Topics Regulatory Compliance

Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval ↗

May 16, 2026

Denali Therapeutics (NASDAQ:DNLI) is seeing early commercial interest for its first approved drug, AVLAYAH, following its March 24 accelerated approval for Hunter syndrome, Chief Operating Officer and...

Via MarketBeat

Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval ↗

May 05, 2026

This biotech company develops therapies for neurodegenerative and rare diseases, supported by clinical assets and pharma collaborations.

Via The Motley Fool

Topics Regulatory Compliance

Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA

April 02, 2026

In a pivotal moment for the rare disease community and the biotechnology sector, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has reached a critical regulatory milestone. The U.S. Food and Drug...

Via MarketMinute

Topics Intellectual Property Lawsuit

The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH

March 26, 2026

On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)...

Via Finterra

Topics Economy Initial Public Offering

Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage

February 06, 2026

Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter and full-year 2025 financial results on February 6, 2026, signaling a definitive shift from a legacy company plagued by patent cliffs to a leaner,...

Via MarketMinute

Topics Intellectual Property

Biggest Stock Movers Today, Dec. 10: PLAB, AVAV, & More ↗

December 10, 2025

Via The Motley Fool

FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate ↗

October 14, 2025

FDA extends review of Denali Therapeutics' tividenofusp alfa for Hunter syndrome to April 2026; analysts remain confident in its approval prospects.

Via Benzinga

What Happened To Denali Therapeutics Stock Wednesday? ↗

April 02, 2025

Denali Therapeutics, Inc. (NASDAQ:DNLI) shares traded higher on Wednesday after the company initiated its biologics license application (BLA) for the accelerated approval of Tividenofusp Alfa for the...

Via Benzinga

Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback ↗

March 06, 2025

Denali Therapeutics' ALS drug DNL343 failed to show efficacy, leading to the discontinuation of the trial extension. Analysts now focus on its Hunter syndrome drug.

Via Benzinga

Why Is Denali Therapeutics Stock Trading Higher On Wednesday? ↗

January 15, 2025

Denali Therapeutics showcases its BBB platform at J.P. Morgan Conference, highlighting DNL310's Hunter syndrome progress and plans for commercialization.

Via Benzinga

Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected ↗

January 07, 2025

Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data and subgroup analyses in 2025.

Via Benzinga

Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet. ↗

January 07, 2025

One analyst says the six-month study was too short and the benefits could appear over time.

Via Investor's Business Daily

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic ↗

January 03, 2025

William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases.

Via Benzinga

This Denali Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Friday ↗

January 03, 2025

Via Benzinga

Denali Therapeutics Stock Is Sliding After The Bell: Here's Why ↗

October 10, 2024

Denali Therapeutics shares are moving lower in Thursday's after-hours session after the company announced that its Phase 2 study of oditrasertib was discontinued.

Via Benzinga

A Biotech Breakout Will Be Led By Small Caps ↗

September 23, 2024

It’s hard to focus on biotech stocks right now because there are many distractions. The Fed and the rate cuts, AI and semiconductor stocks and geopolitical turmoil seemingly worse than ever.

Via Talk Markets

Topics Artificial Intelligence Economy

DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q2 2024 ↗

August 01, 2024

DNLI stock results show that Denali Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Denali Therapeutics Stock Gets Technical Rating Upgrade ↗

July 16, 2024

Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Via Investor's Business Daily

3 Longevity Stocks to Buy for Anti-Aging Breakthroughs ↗

July 08, 2024

Longevity stocks are at the forefront of combating age-related illnesses with transformative AI-driven drug discovery.

Via InvestorPlace

Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗

June 03, 2024

Via Benzinga

Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday ↗

May 08, 2024

Via Benzinga

DNLI Stock Earnings: Denali Therapeutics Beats EPS for Q1 2024 ↗

May 07, 2024

DNLI stock results show that Denali Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

To the Moon and Beyond: 7 Stocks With Cosmic Potential ↗

March 14, 2024

With the Fear and Greed Index at 69, it's an opportune to wager on these attractive Stocks with Moonshot Potential.

Via InvestorPlace

Goldman Sachs Maintains Buy Rating for Denali Therapeutics: Here's What You Need To Know ↗

February 29, 2024

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.